{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:21:39Z","timestamp":1780755699186,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>PET\/MRI is an emerging imaging modality which enables the evaluation and quantification of biochemical processes in tissues, complemented with accurate anatomical information and low radiation exposure. In the framework of theragnosis, PET\/MRI is of special interest due to its ability to delineate small lesions, adequately quantify them, and therefore to plan targeted therapies. The aim of this study was to validate the diagnostic performance of [<jats:sup>68<\/jats:sup>\u00a0Ga]Ga-DOTA-TOC PET\/MRI compared to PET\/CT in advanced disease paragangliomas and pheochromocytomas (PGGLs) to assess in which clinical settings, PET\/MRI may have a greater diagnostic yield.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a same-day protocol with consecutive acquisition of a PET\/CT and a PET\/MRI after a single [<jats:sup>68<\/jats:sup>\u00a0Ga]Ga-DOTA-TOC injection in 25 patients. Intermodality agreement, Krenning Score (KS), SUVmax (Standard Uptake Value), target-to-liver-ratio (TLR), clinical setting, location, and size were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The diagnostic accuracy with PET\/MRI increased by 14.6% compared to PET\/CT especially in bone and liver locations (mean size of new lesions was 3.73\u00a0mm). PET\/MRI revealed a higher overall lesion uptake than PET\/CT (TLR 4.12 vs 2.44) and implied an upward elevation of the KS in up to 60% of patients. The KS changed in 30.4% of the evaluated lesions (mean size 11.89\u00a0mm), in 18.4% of the lesions it increased from KS 2 on PET\/CT to a KS\u2009\u2265\u20093 on PET\/MRI and 24.96% of the lesions per patient with multifocal disease displayed a KS\u2009\u2265\u20093 on PET\/MR, that were not detected or showed lower KS on PET\/CT. In 12% of patients, PET\/MRI modified clinical management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PET\/MRI showed minor advantages over conventional PET\/CT in the detection of new lesions but increased the intensity of SSRs expression in a significant number of them, opening the door to select which patients and clinical settings can benefit from performing PET\/MRI.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-023-00521-6","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T17:04:05Z","timestamp":1673370245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Same-day comparative protocol PET\/CT-PET\/MRI [68\u00a0Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-8557","authenticated-orcid":false,"given":"Stefan","family":"Prado-Wohlwend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Ballesta-Moratalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Torres-Espallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"del Olmo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Bello-Arques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Olivas-Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Merino-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"521_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JWM Lenders","year":"2014","unstructured":"Lenders JWM, Duh Q, Eisenhofer G, Gimenez-Roqueplo A, Grebe SKG, Murad MH, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:1915\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"521_CR2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMra1806651","volume":"381","author":"HPH Neumann","year":"2019","unstructured":"Neumann HPH, Young WF. Eng, C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381:552\u201365.","journal-title":"N Engl J Med"},{"key":"521_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00062","volume":"38","author":"J Crona","year":"2017","unstructured":"Crona J, Ta\u00efeb D, Pacak K. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocr Rev. 2017;38:489\u2013515.","journal-title":"Endocr Rev"},{"key":"521_CR4","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2017-00992","volume":"102","author":"O Hamidi","year":"2017","unstructured":"Hamidi O, Young WF, I\u00f1iguez-Ariza NM, Kittah NE, Gruber L, Bancos C, et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. J Clin Endocrinol Metab. 2017;102:3296\u2013305.","journal-title":"J Clin Endocrinol Metab"},{"key":"521_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/his.13402","volume":"72","author":"J Turchini","year":"2018","unstructured":"Turchini J, Cheung VKY, Tischler AS, De Krijger RR, Gill AJ. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology. 2018;72:97\u2013105.","journal-title":"Histopathology"},{"key":"521_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:839\u201368.","journal-title":"J Natl Compr Canc Netw"},{"key":"521_CR7","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/molecules25174012","volume":"25","author":"R Eychenne","year":"2020","unstructured":"Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules. 2020;25:4012.","journal-title":"Molecules"},{"key":"521_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2967\/jnumed.118.211706","volume":"60","author":"S Han","year":"2019","unstructured":"Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA\u2013Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med. 2019;60:369\u201376.","journal-title":"J Nucl Med"},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2214\/AJR.18.20001","volume":"211","author":"SM Broski","year":"2018","unstructured":"Broski SM, Goenka AH, Kemp BJ, Johnson GB. Clinical PET\/MRI: 2018 Update. AJR Am J Roentgenol. 2018;211:295\u2013313.","journal-title":"AJR Am J Roentgenol"},{"key":"521_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12149-018-1291-7","volume":"32","author":"RA Werner","year":"2018","unstructured":"Werner RA, Bundschuh RA, Bundschuh LA, Javadi MS, Higuchi T, Weich AA, et al. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Ann Nucl Med. 2018;32:512\u201322.","journal-title":"Ann Nucl Med"},{"key":"521_CR11","first-page":"471","volume":"48","author":"S Surti","year":"2007","unstructured":"Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp S. Performance of Philips Gemini TF PET\/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med. 2007;48:471\u201380.","journal-title":"J Nucl Med"},{"key":"521_CR12","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1109\/TMI.2016.2537811","volume":"35","author":"CS Levin","year":"2016","unstructured":"Levin CS, Maramraju SH, Khalighi MM, Deller TW, Delso G, Jansen F. Design Features and Mutual Compatibility Studies of the Time-of-Flight PET Capable GE SIGNA PET\/MR System. IEEE Trans Med Imaging. 2016;35:1907\u201314.","journal-title":"IEEE Trans Med Imaging"},{"key":"521_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/RLU.0000000000001753","volume":"42","author":"D Berzaczy","year":"2017","unstructured":"Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, et al. Whole-Body 68Ga-DOTANOC PET\/MRI Versus 68Ga-DOTANOC PET\/CT in Patients With Neuroendocrine Tumors. Clin Nucl Med. 2017;42:669\u201374.","journal-title":"Clin Nucl Med"},{"key":"521_CR14","first-page":"1109","volume":"10","author":"SY Huang","year":"2014","unstructured":"Huang SY, Savic D, Yang J, Shrestha U, Seo Y. The effect of magnetic field on positron range and spatial resolution in an integrated whole-body time-of-flight PET\/MRI system. IEEE Nucl Sci Symp Conf Rec. 2014;10:1109.","journal-title":"IEEE Nucl Sci Symp Conf Rec"},{"key":"521_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40336-019-00344-1","volume":"7","author":"A Pirasteh","year":"2019","unstructured":"Pirasteh A, Riedl C, Mayerhoefer ME, Giancipoli RG, Larson SM, Bodei L. PET\/MRI for neuroendocrine tumors: a match made in heaven or just another hype? Clin Transl Imaging. 2019;7:405\u201313.","journal-title":"Clin Transl Imaging"},{"key":"521_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejrad.2017.05.029","volume":"93","author":"K Shang","year":"2017","unstructured":"Shang K, Cui B, Ma J, Shuai D, Liang Z, Jansen F, et al. Clinical evaluation of whole-body oncologic PET with time-of-flight and point-spread function for the hybrid PET\/MR system. Eur J Radiol. 2017;93:70\u20135.","journal-title":"Eur J Radiol"},{"key":"521_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2967\/jnumed.115.154757","volume":"57","author":"B Aklan","year":"2016","unstructured":"Aklan B, Oehmigen M, Beiderwellen K, Ruhlmann M, Paulus DH, Jakoby BW, et al. Impact of Point-Spread Function Modeling on PET Image Quality in Integrated PET\/MR Hybrid Imaging. J Nucl Med. 2016;57:78\u201384.","journal-title":"J Nucl Med"},{"key":"521_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmp.2019.04.006","volume":"61","author":"A Olin","year":"2019","unstructured":"Olin A, Krogager L, Rasmussen JH, Andersen FL, Specht L, Beyer T, et al. Preparing data for multiparametric PET\/MR imaging: Influence of PET point spread function modelling and EPI distortion correction on the spatial correlation of [18F]FDG-PET and diffusion-weighted MRI in head and neck cancer. Phys Med. 2019;61:1\u20137.","journal-title":"Phys Med"},{"key":"521_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/RLU.0000000000000289","volume":"39","author":"EM Blanchet","year":"2014","unstructured":"Blanchet EM, Millo C, Martucci V, Maas-Moreno R, Blumke A, Pacak K. Integrated whole-body PET\/MR imaging with 18F-FDG, 18FFDOPA, and 18F-fluorodopamine in paragangliomas, in comparison to PET\/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol. Clin Nucl Med. 2014;39:243\u201350.","journal-title":"Clin Nucl Med"},{"key":"521_CR20","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/MNM.0000000000001048","volume":"40","author":"G Coura-Filho","year":"2019","unstructured":"Coura-Filho G, Hoff A, Duarte P, Buchpiguel C, Josefsson A, Hobbs R, et al. 68Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours. Nucl Med Commun. 2019;40:920\u20136.","journal-title":"Nucl Med Commun"},{"key":"521_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/diagnostics10121083","volume":"10","author":"V Liberini","year":"2020","unstructured":"Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, et al. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics. 2020;10:1083.","journal-title":"Diagnostics"},{"key":"521_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"521_CR23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med. 2019;60:1266\u20139.","journal-title":"J Nucl Med"},{"key":"521_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40658-016-0142-7","volume":"3","author":"AM Karlberg","year":"2016","unstructured":"Karlberg AM, S\u00e6ther O, Eikenes L, Goa PE. Quantitative comparison of PET performance\u2014Siemens Biograph mCT and mMR. EJNMMI Phys. 2016;3:5.","journal-title":"EJNMMI Phys"},{"key":"521_CR25","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1007\/s00330-017-4803-2","volume":"27","author":"LM Sawicki","year":"2017","unstructured":"Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, et al. Evaluation of 68Ga-DOTATOC PET\/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET\/CT. Eur Radiol. 2017;27:4091\u20139.","journal-title":"Eur Radiol"},{"key":"521_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s11547-018-0917-0","volume":"123","author":"F Seith","year":"2018","unstructured":"Seith F, Schraml C, Reischl G, Nikolaou K, Pfannenberg C, la Foug\u00e8re C, et al. Fast non-enhanced abdominal examination protocols in PET\/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET\/CT. Radiol med. 2018;123:860\u201370.","journal-title":"Radiol med"},{"key":"521_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/RLI.0b013e3182871a7f","volume":"48","author":"K Beiderwellen","year":"2013","unstructured":"Beiderwellen K, Poeppel T, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, et al. Simultaneous 68Ga-DOTATOC PET\/MRI in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Initial Results. Invest Radiol. 2013;48:273\u20139.","journal-title":"Invest Radiol"},{"key":"521_CR28","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s00261-015-0409-9","volume":"40","author":"TA Hope","year":"2015","unstructured":"Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, et al. Simultaneous 68Ga-DOTA-TOC PET\/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015;40:1432\u201340.","journal-title":"Abdom Imaging"},{"key":"521_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00259-019-04452-y","volume":"47","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, et al. PET\/MRI versus PET\/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. 2020;47:51\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"521_CR30","first-page":"11","volume":"3","author":"A Cieszanowski","year":"2016","unstructured":"Cieszanowski A, Lisowska A, Dabrowska M, Korczynski P, Zukowska M, Grudzinski IP, et al. MR Imaging of Pulmonary Nodules: Detection Rate and Accuracy of Size Estimation in Comparison to Computed Tomography. PLoS ONE. 2016;3:11.","journal-title":"PLoS ONE"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-023-00521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-023-00521-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-023-00521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T17:04:33Z","timestamp":1673370273000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-023-00521-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1186\/s40644-023-00521-6","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Research from University and Polytechnic Hospital La Fe. Valencia. Spain. Registration number: 2020\u2013432-1. September 23, 2020. Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}